News | Heart Failure | August 24, 2022

Congestive Heart Failure Patients May Be Eligible for Treatment that Could Help Them Live Longer

Patients diagnosed with moderate aortic stenosis and congestive heart failure may qualify to participate in a national clinical trial that includes Memorial Cardiac and Vascular Institute and will determine whether a minimally-invasive valve replacement benefits those who are currently treated only with medication 

Dr. Jonathan Roberts is medical director of Clinical Research and Education, Interventional Cardiology for Memorial Healthcare System and program director of its Cardiology Fellowship program.

Dr. Jonathan Roberts is medical director of Clinical Research and Education, Interventional Cardiology for Memorial Healthcare System and program director of its Cardiology Fellowship program. 


August 24, 2022 — Patients diagnosed with moderate aortic stenosis and congestive heart failure may qualify to participate in a clinical trial that will determine whether a minimally-invasive valve replacement benefits those who are currently treated only with medication. 

The procedure, known by the acronym “TAVR” (Transcatheter Aortic Valve Replacement), is currently only approved for use in patients with severe aortic stenosis. In those cases, the aortic valve is replaced through a transcatheter process that replaces open-heart surgery and has resulted in individuals feeling better, avoiding hospital stays, and living longer. 

To date, TAVR hasn’t been approved as an option for those with moderate aortic stenosis. Those patients currently receive medical therapy and are observed on guideline directed medical treatment until their condition worsens. The national ‘TAVR UNLOAD’ trial Memorial Cardiac and Vascular Institute is participating in seeks to determine whether performing the valve replacement much earlier, before the patient’s condition becomes severe, delivers the same benefits. 

“The exciting part to the patient participating in the TAVR trial is potentially having access to a treatment that otherwise wouldn’t be available to them,” said Dr. Jonathan Roberts, medical director of Clinical Research and Education, Interventional Cardiology for Memorial Healthcare System and program director of its Cardiology Fellowship program. “TAVR is an amazing procedure that we perform quite frequently, but it’s new for us to be doing this on those whose disease hasn’t progressed to its later stages.” 

The clinical trial will randomize patients with moderate aortic stenosis, with 50% of them receiving the TAVR procedure and the other half continuing with traditional medical therapy. Researchers expect the five-year comparison study to produce results that demonstrate whether those who have the procedure earlier get the same benefit as those who undergo TAVR once their heart disease becomes more severe and how those results compare with those who continued with guideline directed medical therapy. “Memorial’s participation in the trial is a direct result of the healthcare system’s ascension as an academic medical center with the expertise and patient volumes required of host facilities,” said Dr. Roberts. 

For more information: mhs.net/services/cardiac-vascular 

 


Related Content

Feature | Cardiovascular Ultrasound | By Paul M Bojarski

Sudden cardiac arrest is a complex and challenging medical emergency because it can occur anywhere at any time and is ...

Home August 23, 2022
Home
News | Cardiovascular Ultrasound

August 9, 2022 — Butterfly Medical, an Israeli medical device company developing a novel minimally invasive solution to ...

Home August 09, 2022
Home
News | Cardiovascular Ultrasound

July 20, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced the first patient ...

Home July 20, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Enhanced features on the Philips EPIQ CVx ultrasound system provide a next level photorealistic 3D rendering, making it ...

Home July 20, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Automated features on the Philips EPIQ CVx cardiology ultrasound system are helping to bring consistency and speed to ...

Home July 07, 2022
Home
News | Cardiovascular Ultrasound

June 15, 2022 — Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non ...

Home June 15, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

The X5-1c transducer from Philips provides enhanced clinical information in transthoracic imaging over a standard phased ...

Home June 14, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Philips recently announced an update to their flagship EPIQ CVx premium cardiology ultrasound system. Watch the video to ...

Home May 31, 2022
Home
News | Cardiovascular Ultrasound

May 10, 2022 — MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies ...

Home May 10, 2022
Home
Feature | Cardiovascular Ultrasound

The global cardiovascular ultrasound systems market was expected to register a CAGR of 5.9% over the forecast period ...

Home May 05, 2022
Home
Subscribe Now